Michael Broxson

Mike brings more than 20 years of biopharma leadership experience across operations, finance, strategy, new product planning, alliance management and corporate development. Before leading Q32 Bio as Chief Executive Officer, Mike was Chief Business and Operating Officer at Goldfinch Bio. In that role he built the G&A functions, oversaw fundraising efforts, and closed strategic transactions with Gilead and Takeda. Mike spent 16 years at Takeda Pharmaceuticals, most recently as vice president and global head of R&D business development. There he led or played a significant role on over 75 transactions exceeding $25 billion in deal value, including the acquisitions of Millennium, Nycomed and Envoy Therapeutics. He also established Takeda’s externalization practice, establishing new ventures and innovative alliances to support R&D assets. Mike began his career as a toxicologist for CH2M Jacobs, a global engineering consulting firm. He holds a B.A. in Economics and an M.S.P.H. in Toxicology from Tulane University, an M.B.A. from the University of Chicago.

Mike is an Advisor of Steritas and also Principal at Tennyson Advisory. His experience and wisdom ensures that Golgi’s world-class technologies will always be deployed to maximum effect.